125
Views
0
CrossRef citations to date
0
Altmetric
Review

Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research

, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1-11 | Received 29 Nov 2022, Accepted 07 Feb 2023, Published online: 18 Feb 2023

References

  • Strand DS, Kim D, Peura DA. 25 Years of Proton Pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.
  • Kalichman L, Livshits G, Kobyliansky E. Indices of body composition and chronic morbidity: a cross-sectional study of a rural population in central Russia. Am J Hum Biol. 2006;18(3):350–358.
  • Boylan MR, Khalili H, Huang ES, et al. Measures of adiposity are associated with increased risk of peptic ulcer. Clin Gastroenterol Hepatol. 2014;12(10):1688–1694.
  • Weatherall R, Shaper AG. Overweight and obesity in middle-aged British men. Eur J Clin Nutr. 1988;42(3):221–231.
  • Kim J, Kim KH, Lee BJ. Association of peptic ulcer disease with obesity, nutritional components, and blood parameters in the Korean population. PLoS One. 2017;12(8):e0183777.
  • El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100(6):1243–1250.
  • Malaty HM, Fraley JK, Abudayyeh S, et al. Obesity and gastroesophageal reflux disease and gastroesophageal reflux symptoms in children. Clin Exp Gastroenterol. 2009;2:31–36.
  • Freedman DS. Centers for Disease C, Prevention. Obesity - United States, 1988-2008. MMWR Suppl. 2011;60(1):73–77.
  • Lovegrove C. Obesity is linked with increased risk of gastroesophageal reflux disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2(11):501.
  • Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2021;109(6):1417–1423.
  • Benmassaoud A, McDonald EG, Lee TC. Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. Cmaj. 2016;188(9):657–662.
  • Smit C, De Hoogd S, Bruggemann RJM, et al. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14(3):275–285.
  • Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5(7):161.
  • WHO. Obesity and overweight 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  • Prevention CfDCa. Defining adult overweight and obesity 2022. Available from: https://www.cdc.gov/obesity/basics/adult-defining.html
  • Prevention CfDCa. Defining childhood weight status 2022. Available from: https://www.cdc.gov/obesity/basics/childhood-defining.html
  • Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014;43(1):1417–1423.
  • El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut. 2007;56(6):749–755.
  • Pandolfino JE, El–Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639–649.
  • de Vries DR, van Herwaarden MA, Smout AJ, et al. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol. 2008;103(6):1349–1354.
  • Shah SL, Lacy BE, DiBaise JK, et al. The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy. Aliment Pharmacol Ther. 2015;42(9):1093–1100.
  • Shakhnovich V, Smith PB, Guptill JT, et al. Obese children require lower doses of pantoprazole than nonobese peers to achieve equal systemic drug exposures. J Pediatr. 2018;193:102–108 e1.
  • Gerhart JG, Carreno FO, Edginton AN, et al. Development and evaluation of a virtual population of children with obesity for physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2022;61(2):307–320.
  • Berton M, Bettonte S, Stader F, et al. Repository describing the anatomical, physiological, and biological changes in an obese population to inform physiologically based pharmacokinetic models. Clin Pharmacokinet. 2022;61(9):1251–1270.
  • Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–e1010.
  • Knibbe CA, Brill MJ, van Rongen A, et al. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149–167.
  • Krogstad V, Peric A, Robertsen I, et al. Correlation of body weight and composition with hepatic activities of cytochrome p450 enzymes. J Pharm Sci. 2021;110(1):432–437.
  • Ulvestad M, Skottheim IB, Jakobsen GS, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013;93(3):275–282.
  • Teixeira TF, Souza NC, Chiarello PG, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr. 2012;31(5):735–740.
  • Asad Mansoor NM. Volume of Distribution: StatPearls; 2022 [cited 2022]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545280/
  • Kocz AZGSBPR. Drug elimination: StatPearls; 2022 [cited 2022]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547662/
  • Preuss. STSCV. drug metabolism: StatPearls; 2022 [cited 2022]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK442023/
  • Chen K, Luo P, Yang G, et al. Population pharmacokinetics of omeprazole in obese and normal-weight adults. Expert Rev Clin Pharmacol. 2022;15(4):461–471.
  • Shakhnovich V, Brian Smith P, Guptill JT, et al. A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents. Paediatr Drugs. 2018; 20(5):483–495.
  • Kovesdy CP, Furth SL, Zoccali C, et al. Obesity and kidney disease: hidden consequences of the epidemic. Can J Kidney Health Dis. 2017;4:2054358117698669.
  • Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, et al. OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes. 2011;60(1):168–176.
  • Neely M, Jelliffe R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol. 2010;50(7):842–847.
  • Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008;48(9):1081–1091.
  • Peck RW, Shahin MH, Vinks AA. Precision dosing: the clinical pharmacology of goldilocks. Clin Pharmacol Ther. 2021;109(1):11–14.
  • Vaughns JD, Conklin LS, Long Y, et al. Obesity and pediatric drug development. J Clin Pharmacol. 2018;58(5):650–661.
  • Must A, Anderson SE. Body mass index in children and adolescents: considerations for population-based applications. Int J Obes (Lond). 2006;30(4):590–594.
  • Harskamp-van Ginkel MW, Hill KD, Becker KC, et al. Drug dosing and pharmacokinetics in children with obesity: a systematic review. JAMA Pediatr. 2015;169(7):678–685.
  • Luo L, Liu M. Adipose tissue in control of metabolism. J Endocrinol. 2016;231(3):R77–R99.
  • Shakhnovich V, Abdel-Rahman S, Friesen CA, et al. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Pediatr Obes. 2019; 14(1):e12459.
  • Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35.
  • Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304.
  • Shakhnovich V, Abdel-Rahman S, Chan S, et al. American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2021;109:S5–S88.
  • de Jong LM, Jiskoot W, Swen JJ, et al. Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics. Genes (Basel). 2020;11:12.
  • Christensen H, Hermann M. Immunological response as a source to variability in drug metabolism and transport. Front Pharmacol. 2012;3:8.
  • Chen WY, Chang WL, Tsai YC, et al. Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. Am J Gastroenterol. 2010;105(5):1046–1052.
  • Belhocine K, Vavasseur F, Volteau C, et al. Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. BMC Gastroenterol. 2014;14:128.
  • Luo JY, Niu CY, Wang XQ, et al. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J Gastroenterol. 2003;9(11):2583–2586.
  • Sheu BS, Cheng HC, Chang WL, et al. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol. 2007;102(11):2387–2394.
  • Sheu B-S, Chang W-L, Cheng H-C, et al. Body mass index can determine the healing of reflux esophagitis with los angeles grades C and D by Esomeprazole. Am J Gastroenterol. 2008;103(9):2209–2214.
  • Portoles-Perez A, Paterna ABR, Sanchez Pernaute A, et al. Effect of obesity and roux-en-y gastric surgery on omeprazole pharmacokinetics. Obes Facts. 2022;15(2):271–280.
  • Mitrov-Winkelmolen L, van Buul-Gast MW, Swank DJ, et al. The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study. Obes Surg. 2016;26(9):2051–2058.
  • Kvitne KE, Krogstad V, Wegler C, et al. Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity. Br J Clin Pharmacol. 2022;88(9):4121–4133.
  • Lima JJ, Lang JE, Mougey EB, et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr. 2013;163(3):686–691.
  • Cicali EJ, Blake K, Gong Y, et al. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: a Pilot, Randomized, Multisite Pragmatic Trial. Clin Transl Sci. 2019;12(2):172–179.
  • Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–2056. quiz 2057.
  • Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–1019.
  • Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–1010.
  • Law EH, Badowski M, Hung YT, et al. Association Between Proton Pump Inhibitors and Microscopic Colitis. Ann Pharmacother. 2017;51(3):253–263.
  • Verhaegh BP, de Vries F, Masclee AA, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):1004–1013.
  • Willems RPJ, van Dijk K, Ket JCF, et al. Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms: a Systematic Review and Meta-analysis. JAMA Intern Med. 2020;180(4):561–571.
  • Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120(3):211–215.
  • Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–2442.
  • Hess MW, Hoenderop JG, Bindels RJ, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405–413.
  • Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–1241.
  • Ajmera AV, Shastri GS, Gajera MJ, et al. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther. 2012;19(3):185–189.
  • Hutchinson C, Geissler CA, Powell JJ, et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291–1295.
  • McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104(Suppl 2):S5–9.
  • Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123–125.
  • Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21–25.
  • Sampathkumar K, Ramalingam R, Prabakar A, et al. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol. 2013;23(4):304–307.
  • Ra A, Tobe SW. Acute interstitial nephritis due to pantoprazole. Ann Pharmacother. 2004;38(1):41–45.
  • Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis. 2014;64(4):558–566.
  • Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768–776.
  • Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26(10):2501–2507.
  • Stark CM, Nylund CM. Side effects and complications of proton pump inhibitors: a pediatric perspective. J Pediatr. 2016;168:16–22.
  • Chung EY, Yardley J. Are there risks associated with empiric acid suppression treatment of infants and children suspected of having gastroesophageal reflux disease? Hosp Pediatr. 2013;3(1):16–23.
  • Chen Y-H, Lin K-H, Wang H-M, et al. The efficacies of esomeprazole- versus pantoprazole-based reverse hybrid therapy for Helicobacter pylori eradication. Adv Dige Med. 2018;5(1–2): 26–32
  • Hosey CM, Halpin K, Shakhnovich V, et al. Pediatric growth patterns in youth-onset type 2 diabetes mellitus: implications for physiologically-based pharmacokinetic models. Clin Transl Sci. 2022;15(4):912–922.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.